RISS 검색 - 국내학술지논문

무료
기관 내 무료
유료

내보내기
내책장담기
한글로보기

정확도순

내림차순

내림차순

10개씩 출력

1
가루, 크럼블 및 펠렛사료 급여가 브로일러육의 이화학적특성에 미치는 영향

조헌조,강신곤,차용호,김병기,우선창,여영수 한국동물자원과학회 2002 한국축산학회지 Vol.44 No.5
- 원문보기 3
 ScienceON
 
 KCI
 
 KISS
본 시험은 대형육계에 있어서 생산체계를 조사하기 위하여 영양수준(2∼3주령, ME 2,843㎉/㎏, 체 19.46%; 4∼6주령, ME 3,072㎉/㎏, 체 17.85%; 7∼8주령, ME 3,109㎉/㎏, 체 17.26%)에 따른 사료가공형태(대조구: 가루→크럼블→펠렛 ; 처리1구 : 가루→크럼블→펠렛 ; 처리2구 : 크럼블→크럼블→펠렛 ; 처리3구 : 펠렛→펠렛→펠렛)로 활성탄(1%)을 혼합첨가하여 8주(56일간)동안 실험한 결과는 다음과 같다. 계육의 일반성분에서 조단백질 함량이 22.22∼23.40%였고, 조지방 함량은 0.30∼0.45% 범위로서 처리구가 낮았으며, 특히 처리2구는 0.28로서 가장 낮았다(P<0.05). 계육의 가열감량은 대조구가 높은 경향이었고, 전단력과 pH는 처리3구가(1.21㎏, 5.85) 낮은 경향이었다. 육색에서 명도(L)는 대조구와 처리2구가 가장 밝았고, 적색도(a)는 0.19∼0.85의 범위였고, 황색도(b)는 처리1구가 가장 낮았다. 관능검사와 조직감, 향미에서 시험구간에서는 유의차는 없었다(P<0.05). 지방산에서의 myristic acid와 arachidoic acid는 처리1구가, oleic acid과 지방의 불포화도가 처리2구가 가장 높았다(P<0.05). 또한 아미노산에서 cystine, glutamic acid, valine, iso-leucine, leucine, lysine, arginine은 처리1구와 처리2구가 다른 처리구보다 높게 나타났다(P<0.05). This study was conducted to investigate the effect of nutrient level (metabolizable energy and crude protein, 2,843㎉/㎏ and 19.46% at 2 to 3 week, 3,072㎉/㎏ and 18.38% at 4 to 6 week, 3,109㎉/㎏ and 17.26% at 7 to 8 week, respectively, and feeding form was ground → crumble → pellet in control, ground → crumble → pellet in treatment 1, crumble → crumble → pellet in treatment 2, pellet → pellet → pellet in treatment 3 for broiler during 8 weeks. Also the effects of supplemented with charcoal(1%) in total mixed treatment feed was investigated. The crude protein, crude fat in broiler meat range from 22.22∼23.40%, and 0.30∼0.45%, respectively. Especially, treatment 2 was lower than other treatment (P<0.05). The heating loss tend to be increased at control. Shear force and pH tend to be decreased at T3(1.21㎏, 5.89). Control and T2 were significantly lighter in color (“L”) than the T1 and the “a” ranged from 0.19∼0.85 and T1 was the lowest “b” among other treatment. The panel test, texture, Aroma were not significantly among the an experimental group (P<0.05). Myristic acid and arachidonic acid of T1 was significantly higher than that other treatment and oleic acid, U/S(unsaturated/ saturated) rate T2 was significantly higher than other experimental group(P<0.05). Among amino acid, cystine, glutamic acid, valine, iso-leucine, leucine, lysine, arginine in T1 and T2 was higher than control and T3.
2
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival

Yap, Y S,Cornelio, G H,Devi, B C R,Khorprasert, C,Kim, S B,Kim, T Y,Lee, S C,Park, Y H,Sohn, J H,Sutandyo, N,Wong, D W Y,Kobayashi, M,Landis, S H,Yeoh, E M,Moon, H,Ro, J Nature Publishing Group 2012 The British journal of cancer Vol.107 No.7
- 원문보기
Background:In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. We studied the treatment patterns of these patients in Asia to evaluate the impact of anti-HER2 treatment on the time to occurrence of brain metastases (TTBM) and survival after brain metastasis (BM).Methods:A retrospective study of HER2-positive breast cancer patients diagnosed with BM between January 2006 and December 2008 in six Asian countries was conducted. Demographics, tumour characteristics, treatment details, and events dates were collected from medical records.Results:Data from 280 patients were analysed. Before BM, 63% received anti-HER2 treatment. These patients had significantly longer TTBM than those without anti-HER2 treatment (median 33 vs 19 months; P<0.002). After BM, 93% received radiotherapy, 57% received chemotherapy, and 41% received anti-HER2 treatment (trastuzumab and/or lapatinib). Use of both anti-HER2 agents, primarily sequentially, after BM demonstrated the longest survival after BM and was associated with a significant survival benefit over no anti-HER2 treatment (median 26 vs 6 months; hazard ratio 0.37; 95% CI 0.19–0.72).Conclusion:Anti-HER2 treatment before BM was associated with longer TTBM. Anti-HER2 treatment after BM was associated with a survival benefit, especially when both trastuzumab and lapatinib were utilised.
3
Permeability of Pyrolysing Wood

R. Yuen,R. Casey,G. De Vahl Davis,E. Leonardi,G. H. Yeoh,V. Chandrasekaran 대한기계학회 1998 Heat transter conference Vol.4 No.1
- 원문보기